TipRanks tools are all you need to make data-driven investment decisions. Conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts, with ease.
The Sorrento Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.
What was Sorrento Therapeutics’s price range in the past 12 months?
Sorrento Therapeutics lowest stock price was $5.17 and its highest was $17.25 in the past 12 months.
What is Sorrento Therapeutics’s market cap?
Sorrento Therapeutics’s market cap is $2.34B.
What is Sorrento Therapeutics’s price target?
The average price target for Sorrento Therapeutics is $26.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $26.00 ,the lowest forecast is $26.00. The average price target represents 231.63% Increase from the current price of $7.84.
What do analysts say about Sorrento Therapeutics?
Sorrento Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
When is Sorrento Therapeutics’s upcoming earnings report date?
Sorrento Therapeutics’s upcoming earnings report date is Nov 11, 2021 which is in 2 months.
How were Sorrento Therapeutics’s earnings last quarter?
Sorrento Therapeutics released its earnings results on Aug 06, 2021. The company reported -$0.574 earnings per share for the quarter, missing the consensus estimate of -$0.365 by -$0.209.
Is Sorrento Therapeutics overvalued?
According to Wall Street analysts Sorrento Therapeutics’s price is currently Undervalued.
Does Sorrento Therapeutics pay dividends?
Sorrento Therapeutics does not currently pay dividends.
What is Sorrento Therapeutics’s EPS estimate?
Sorrento Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sorrento Therapeutics have?
Sorrento Therapeutics has 298,100,000 shares outstanding.
What happened to Sorrento Therapeutics’s price movement after its last earnings report?
Sorrento Therapeutics reported an EPS of -$0.574 in its last earnings report, missing expectations of -$0.365. Following the earnings report the stock price went up 2.703%.
Which hedge fund is a major shareholder of Sorrento Therapeutics?
Among the largest hedge funds holding Sorrento Therapeutics’s share is Coatue Management, LLC. It holds Sorrento Therapeutics’s shares valued at N/A.